| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
Penicillin-binding proteins (PBPs). Cefuroxime Sodium inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) located in the bacterial cell membrane. This inhibits the transpeptidase enzyme, preventing cross-linking of peptidoglycan chains, which leads to bacterial cell lysis and death. The compound is a beta-lactam antibiotic with broad-spectrum activity.
|
|---|---|
| ln Vitro |
Cefuroxime sodium exhibits great efficacy against Staphylococcus aureus (MIC=0.25 μg/ml), irrespective of the strain's penicillinase production. The minimum inhibitory concentration (MIC) values for methicillin-susceptible Staphylococcus aureus, methicillin-resistant Staphylococcus pyogenes, Streptococcus pneumoniae, viridans Streptococcus, Streptococcus faecalis, and Clostridium spp. are 0.25 μg/ml, 5.9 μg/ml, 0.125 μg/ml, 0.125 μg/ml, >125.0 μg/ml, and 1.2 μg/ml, respectively [1]. Even while cefuroxime sodium (10-100 μg/ml; 2–6) acts slowly on Staphylococcus aureus strains, it nonetheless has a fast bactericidal impact and can kill over 99% of the initial strains in just 6 hours of inoculation. Gram-negative bacteria are promptly eliminated; in most situations, more than 99% of large inocula are eliminated in less than two hours; strains that generate beta-lactamases are eliminated at a rate that is equivalent to that of strains lacking the enzyme [1].
Cefuroxime Sodium demonstrates broad-spectrum antibacterial activity in vitro against Gram-positive and Gram-negative bacteria. It is active against Staphylococcus aureus (including beta-lactamase-producing strains), Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, Klebsiella species, and other organisms. The compound's antibacterial activity has been characterized in susceptibility testing against clinical isolates. |
| ln Vivo |
Rabbits (body weight 2.0-2.5 kg) were intravenously injected with Staphylococcus aureus strain 630 (penicillinase-producing strain), and the protection test findings showed that the median effective dose of cefuroxime sodium was 3 mg/kg [2].
In vivo, Cefuroxime Sodium is used clinically for the treatment of serious bacterial infections. It is administered intravenously or intramuscularly and achieves therapeutic concentrations in plasma and tissues. The drug is effective against a wide range of infections, including pneumonia, urinary tract infections, and sepsis. It is also used for surgical prophylaxis to prevent postoperative infections. |
| Enzyme Assay |
In vitro antibacterial susceptibility testing for Cefuroxime Sodium involves determining minimum inhibitory concentrations (MICs) against bacterial isolates using broth microdilution or agar dilution methods. The compound is tested at varying concentrations, and bacterial growth is measured. MIC values are interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines.
|
| Cell Assay |
Cellular assays are not applicable for Cefuroxime Sodium, as it acts directly on bacteria. However, the compound's effects on bacterial growth can be assessed in bacterial cultures. Time-kill assays may be performed to determine bactericidal activity. The compound's stability to beta-lactamases can be assessed using enzyme assays.
|
| Animal Protocol |
In vivo animal studies for Cefuroxime Sodium are typically efficacy studies in murine models of infection. The compound is administered parenterally, and bacterial clearance, survival, and tissue bacterial counts are assessed. Pharmacokinetic studies have also been performed to characterize its distribution and elimination in animal models. Dosing regimens are based on clinical protocols.
|
| ADME/Pharmacokinetics |
Cefuroxime Sodium is administered intravenously or intramuscularly. It is distributed widely in body tissues and fluids, including the lungs, kidneys, and cerebrospinal fluid (when meninges are inflamed). The drug is not absorbed orally (cefuroxime axetil is the oral prodrug). It is excreted renally by glomerular filtration and tubular secretion. The half-life is approximately 1-1.5 hours in patients with normal renal function.
|
| Toxicity/Toxicokinetics |
Cefuroxime Sodium is generally well-tolerated. Common side effects include gastrointestinal disturbances, rash, and injection site reactions. Serious adverse effects include anaphylaxis, Clostridium difficile-associated diarrhea, and hematological abnormalities. The drug is contraindicated in patients with a history of hypersensitivity to cephalosporins. Dose adjustment is required in patients with renal impairment.
|
| References | |
| Additional Infomation |
Cefuroxime sodium is an organic molecular entity. Cefuroxime sodium is the sodium salt of cefuroxime, a semi-synthetic, broad-spectrum, β-lactamase-resistant second-generation cephalosporin antibiotic with bactericidal activity. Cefuroxime sodium inhibits bacterial cell wall synthesis by inactivating penicillin-binding proteins (PBPs), thereby interfering with the final transpeptidation step required for peptidoglycan unit cross-linking, which is a component of the cell wall. Lack of cross-linking leads to decreased cell wall stability, ultimately resulting in cell lysis. This is a β-lactamase-resistant, broad-spectrum cephalosporin antibiotic. It has been recommended for the treatment of Gram-negative and Gram-positive bacterial infections, gonorrhea, and Haemophilus infections. See also: Cefuroxime (containing the active fraction).
Cefuroxime Sodium is a second-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It is used clinically for the treatment of serious infections and surgical prophylaxis. The drug is administered parenterally and is stable to many beta-lactamases. It is available as a sterile powder for reconstitution and is an FDA-approved therapeutic agent. |
| Molecular Formula |
C16H15N4NAO8S
|
|---|---|
| Molecular Weight |
446.3671
|
| Exact Mass |
446.05
|
| CAS # |
56238-63-2
|
| Related CAS # |
Cefuroxime;55268-75-2;Cefuroxime axetil;64544-07-6;Cefuroxime-d3;1803240-98-3
|
| PubChem CID |
23670318
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
240-245°C(dec)
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
30
|
| Complexity |
804
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CO/N=C(/C1=CC=CO1)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)[O-].[Na+]
|
| InChi Key |
URDOHUPGIOGTKV-JTBFTWTJSA-M
|
| InChi Code |
InChI=1S/C16H16N4O8S.Na/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20;/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24);/q;+1/p-1/b19-9-;/t10-,14-;/m1./s1
|
| Chemical Name |
sodium;(6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~224.03 mM)
H2O : ~50 mg/mL (~112.01 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 55 mg/mL (123.22 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2403 mL | 11.2015 mL | 22.4029 mL | |
| 5 mM | 0.4481 mL | 2.2403 mL | 4.4806 mL | |
| 10 mM | 0.2240 mL | 1.1201 mL | 2.2403 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05609240 | Recruiting | Drug: Cefuroxime | Antibiotic Prophylaxis Colorectal Surgery |
University of Leeds | 2023-05-10 | Phase 2 | 2020-12-26
| NCT03141476 | Completed | Drug: Cefuroxime 1,5g Drug: Cefuroxime 3g Drug: Cefuroxime 4,5g |
Obesity; Drug | Universitätsklinikum Hamburg-Eppendorf | 2017-03-01 | Phase 4 |
| NCT06527560 | Recruiting | Drug: Cefuroxime Drug: Cefuroxime Axetil |
Pyelonephritis in Pregnancy | Hospital de Clinicas de Porto Alegre | 2024-09-09 | Phase 4 |
| NCT04616352 | Completed | Other: Resistance to cefuroxime | Urinary Tract Infections | Universidad Nacional de Colombia | 2020-12-26 | |
| Unknown status | NCT04212078 | Drug: Levofloxacin Ophthalmic Drug: Cefuroxime |
Endophthalmitis Postoperative | National University of Malaysia | 2019-07-29 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
